Tags

Type your tag names separated by a space and hit enter

Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
Int J Urol. 2006 Sep; 13(9):1202-6.IJ

Abstract

AIM

To examine the efficiency of alpha1-blocker treatment on disease-specific and generic quality of life (QOL) in men with clinically diagnosed benign prostatic hyperplasia (BPH), the improvement of QOL scores with International prostate symptom score (I-PSS) and Rand Medical Outcomes Study 36-item Health Survey (SF-36) was prospectively analyzed.

METHODS

A total of 68 newly diagnosed patients with symptomatic BPH that satisfied all inclusion and none of the exclusion criteria were prospectively recruited. All patients received 0.2 mg/day of tamsulosin for 12 weeks. All patients underwent pretreatment documentation of lower urinary tract symptoms (LUTS) and assessment of symptom-specific QOL. Symptoms and general health-related QOL (HRQOL) were assessed using the I-PSS and SF-36, respectively. Also, other objective variables, such as prostate volume, maximal urinary flow and postvoid residual urine volume, were evaluated.

RESULTS

After 12 weeks, decrease in I-PSS was 27% compared with baseline (from 16.4 +/- 7.18 to 11.9 +/- 7.56). All questionnaires in the I-PSS showed improvement after tamsulosin treatment and the I-PSS QOL score was improved from 4.51 +/- 1.14 to 3.17 +/- 1.38 (P < 0.0001) at 12 weeks after tamsulosin administration. In intragroup comparisons of HRQOL scores with age-gender adjusted SF-36 Japanese national norms, three SF-36 subscales (bodily pain, BP; social function, SF; and mental health, MH) were worse in the BPH group aged over 70 years, while younger BPH groups aged <70 had better mean SF-36 physical function (PF) scores compared with age-gender adjusted Japanese national norms. In the BPH group with a prostatic volume > or =20 mL, three mean SF-36 scales (BP, SF and MH) were significantly improved after tamsulosin treatment. It is noteworthy that these SF-36 subscales were identical to those observed to worsen in the older BPH group compared to Japanese national norms.

CONCLUSIONS

Treatment with tamsulosin for symptomatic BPH patients is associated with significant improvement in the generic HRQOL, in addition to disease-specific QOL and symptoms, at 3 months after drug administration. In particularly, for generic HRQOL with SF-36, tamsulosin treatment can efficiently improve three mean SF-36 subscales (BP, SF and MH) that are decreased in older BPH patients.

Authors+Show Affiliations

Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. hirosuzu@faculty.chiba-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16984553

Citation

Suzuki, Hiroyoshi, et al. "Clinical Impact of Tamsulosin On Generic and Symptom-specific Quality of Life for Benign Prostatic Hyperplasia Patients: Using International Prostate Symptom Score and Rand Medical Outcomes Study 36-item Health Survey." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 13, no. 9, 2006, pp. 1202-6.
Suzuki H, Yano M, Awa Y, et al. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey. Int J Urol. 2006;13(9):1202-6.
Suzuki, H., Yano, M., Awa, Y., Nakatsu, H., Egoshi, K., Mikami, K., Ota, S., Okano, T., Hamano, S., Ohki, T., Furuya, Y., & Ichikawa, T. (2006). Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey. International Journal of Urology : Official Journal of the Japanese Urological Association, 13(9), 1202-6.
Suzuki H, et al. Clinical Impact of Tamsulosin On Generic and Symptom-specific Quality of Life for Benign Prostatic Hyperplasia Patients: Using International Prostate Symptom Score and Rand Medical Outcomes Study 36-item Health Survey. Int J Urol. 2006;13(9):1202-6. PubMed PMID: 16984553.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey. AU - Suzuki,Hiroyoshi, AU - Yano,Masashi, AU - Awa,Yusuke, AU - Nakatsu,Hiroomi, AU - Egoshi,Ken-Ichi, AU - Mikami,Kazuo, AU - Ota,Sho, AU - Okano,Tatsuya, AU - Hamano,Satoru, AU - Ohki,Takemasa, AU - Furuya,Yuzo, AU - Ichikawa,Tomohiko, PY - 2006/9/21/pubmed PY - 2007/1/19/medline PY - 2006/9/21/entrez SP - 1202 EP - 6 JF - International journal of urology : official journal of the Japanese Urological Association JO - Int J Urol VL - 13 IS - 9 N2 - AIM: To examine the efficiency of alpha1-blocker treatment on disease-specific and generic quality of life (QOL) in men with clinically diagnosed benign prostatic hyperplasia (BPH), the improvement of QOL scores with International prostate symptom score (I-PSS) and Rand Medical Outcomes Study 36-item Health Survey (SF-36) was prospectively analyzed. METHODS: A total of 68 newly diagnosed patients with symptomatic BPH that satisfied all inclusion and none of the exclusion criteria were prospectively recruited. All patients received 0.2 mg/day of tamsulosin for 12 weeks. All patients underwent pretreatment documentation of lower urinary tract symptoms (LUTS) and assessment of symptom-specific QOL. Symptoms and general health-related QOL (HRQOL) were assessed using the I-PSS and SF-36, respectively. Also, other objective variables, such as prostate volume, maximal urinary flow and postvoid residual urine volume, were evaluated. RESULTS: After 12 weeks, decrease in I-PSS was 27% compared with baseline (from 16.4 +/- 7.18 to 11.9 +/- 7.56). All questionnaires in the I-PSS showed improvement after tamsulosin treatment and the I-PSS QOL score was improved from 4.51 +/- 1.14 to 3.17 +/- 1.38 (P < 0.0001) at 12 weeks after tamsulosin administration. In intragroup comparisons of HRQOL scores with age-gender adjusted SF-36 Japanese national norms, three SF-36 subscales (bodily pain, BP; social function, SF; and mental health, MH) were worse in the BPH group aged over 70 years, while younger BPH groups aged <70 had better mean SF-36 physical function (PF) scores compared with age-gender adjusted Japanese national norms. In the BPH group with a prostatic volume > or =20 mL, three mean SF-36 scales (BP, SF and MH) were significantly improved after tamsulosin treatment. It is noteworthy that these SF-36 subscales were identical to those observed to worsen in the older BPH group compared to Japanese national norms. CONCLUSIONS: Treatment with tamsulosin for symptomatic BPH patients is associated with significant improvement in the generic HRQOL, in addition to disease-specific QOL and symptoms, at 3 months after drug administration. In particularly, for generic HRQOL with SF-36, tamsulosin treatment can efficiently improve three mean SF-36 subscales (BP, SF and MH) that are decreased in older BPH patients. SN - 0919-8172 UR - https://www.unboundmedicine.com/medline/citation/16984553/Clinical_impact_of_tamsulosin_on_generic_and_symptom_specific_quality_of_life_for_benign_prostatic_hyperplasia_patients:_using_international_prostate_symptom_score_and_Rand_Medical_Outcomes_Study_36_item_Health_Survey_ L2 - https://doi.org/10.1111/j.1442-2042.2006.01594.x DB - PRIME DP - Unbound Medicine ER -